西地那非对肺动脉高压大鼠肺动脉压力影响的实验研究  

Prevent and reverse effects of sildenafil on pulmonary hypertension in pneumonectomy combining to monocrotaline treated rats

作　　者：刘浩[1] 关勤[1] 刘志勇[1] 

机构地区：[1]东南大学附属中大医院心胸外科,江苏南京210009

出　　处：《现代医学》2006年第3期154-157,共4页Modern Medical Journal

摘　　要：目的研究西地那非对肺动脉高压发生、发展的延缓及逆转作用,探讨其与内皮素系统的关系。方法单侧肺切除1周后叠加野百合碱60 mg.kg-1皮下注射建立肺动脉高压大鼠模型,在野百合碱注射后治疗组大鼠给予西地那非1.7 mg.kg-1.d-1,3周后测量大鼠平均肺动脉压(mPAP)、右心室重量与(左心室+室间隔)重量比值[RV/(LV+S)]、肺小血管管壁厚度与血管外径比值,免疫组织化学检测大鼠肺小血管壁平滑肌细胞内皮素-1A型受体(ETA-R)的表达,放射免疫法检测血浆内皮素-1浓度。结果治疗组大鼠mPAP、[RV/(LV+S)]、肺小血管管壁厚度与血管外径比值均低于对照组(P<0.05),肺小血管壁平滑肌细胞ETA-R的表达较对照组降低(P<0.05),血浆内皮素-1浓度较对照组升高,但无统计学意义。结论西地那非对单侧肺切除叠加野百合碱注射引起的肺动脉高压、右心室肥厚及肺血管结构重建具有良好的延缓和逆转作用。Objective To investigate the protective and reverse effects of sildenafil on pulmonary hypertension in pneumonectomy combining to monocrotaline treated rats. Method The SD rats were randomly divided into the shamed-operation group, the control group and the treament group. All the rats were treated with monocrotaline （60 mg·kg^-1） one week after pneumonectomy. The treament group was treated with sidenafil （ 1.7 mg·kg^-1·d^-1 ） for 3 weeks. The mean pulmonary arterial pressure（mPAP） and right ventricle/left ven- tricle and septum [ RV/（ LV ＋ S） ] were measured and the small pulmonary arterial morphologic changes were observed with morphmetric analysis under microscopes. Immunohistochemistry was used to determine the expression of endothelin-1 A type receptor（ ETA-R） on small pumlonary arterial and radioimmunity was used to determine the ET-1 level in plasma. Results The mPAP, [ RV/（ LV ＋ S） ], small pumlonary arterial morphologic changes were highly improved in sildenafil group（ P〈0.05 ）. The expression of ETA-R on small pumlonary arterial was significently reduced in treament group（ P〈0.05 ）. The ET-1 level in plasma was increased in treament group, but not reach the significant. Conclusion Sildenafil can prevent and reverse the development of pulmonary hypertension in pneumonectomy combining to monocrotaline treated rats.

关 键 词：西地那非 肺动脉高压 内皮素 内皮素受体 

分 类 号：R-33[医药卫生] R543.2